Bone Marrow TransplantationTransplantation, HomologousGraft vs Host DiseaseBone MarrowHematologic NeoplasmsLeukemiaWhole-Body IrradiationBone Marrow CellsTransplantation ConditioningAnemia, AplasticTransplantation, AutologousTransplantation ChimeraBusulfanTissue DonorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHematopoietic Stem Cell TransplantationGraft SurvivalHistocompatibility TestingLeukocyte TransfusionGraft vs Tumor EffectRecurrenceHistocompatibilityLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaCyclophosphamideRemission InductionLymphocyte DepletionRadiation ChimeraGraft vs Leukemia EffectGraft vs Host ReactionAcute DiseaseLeukemia, MyeloidLymphocyte TransfusionTransplantation, IsogeneicHepatic Veno-Occlusive DiseaseImmunosuppressive AgentsBone and BonesMyelodysplastic SyndromesCombined Modality TherapyTreatment OutcomeHematopoietic Stem CellsBone Marrow PurgingMice, Inbred C57BLT-LymphocytesChimeraImmunosuppressionTime FactorsHematopoiesisNuclear FamilyCyclosporineSurvival AnalysisTransplantation ImmunologyGraft RejectionLymphoma, Non-HodgkinLiver TransplantationRetrospective StudiesActuarial AnalysisHLA AntigensHematologic DiseasesCytomegalovirus InfectionsLymphomaFatal OutcomeSurvival RateMice, Inbred BALB CCytarabineSevere Combined ImmunodeficiencyAntineoplastic Combined Chemotherapy ProtocolsMultiple MyelomaFollow-Up StudiesDisease-Free SurvivalBone Marrow DiseasesImmunocompromised HostKidney TransplantationAnemia, Refractory, with Excess of BlastsGranulocyte Colony-Stimulating FactorStem Cell TransplantationLeukocyte CountPancytopeniaInfectionSpleenMethotrexatePrognosisLeukemia, Myelomonocytic, AcuteEtoposideAntilymphocyte SerumFlow CytometryNeoplasm, ResidualBone Marrow ExaminationImmunophenotypingMinor Histocompatibility AntigensSalvage TherapyCyclosporinsAntibodies, MonoclonalGanciclovirLymphoproliferative DisordersBone RemodelingColony-Forming Units AssayLymphocyte ActivationMice, Inbred AKRAntigens, CD